189 related articles for article (PubMed ID: 22217111)
41. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
[TBL] [Abstract][Full Text] [Related]
42. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
Ott U; Sauerbrei A; Lange J; Schäfler A; Walther M; Wolf G; Wutzler P; Zell R; Krumbholz A
Med Microbiol Immunol; 2012 Aug; 201(3):297-302. PubMed ID: 22350187
[TBL] [Abstract][Full Text] [Related]
43. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
Tsatsaris V; Capitant C; Schmitz T; Chazallon C; Bulifon S; Riethmuller D; Picone O; Poulain P; Lewin F; Lainé F; Jacqz-Aigrain E; Aboulker JP; Launay O;
Ann Intern Med; 2011 Dec; 155(11):733-41. PubMed ID: 22147712
[TBL] [Abstract][Full Text] [Related]
44. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
[TBL] [Abstract][Full Text] [Related]
45. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
[TBL] [Abstract][Full Text] [Related]
46. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
[TBL] [Abstract][Full Text] [Related]
47. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
48. Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan.
Uno S; Kimachi K; Matsuo F; Miyazaki K; Oohama A; Kei J; Nishimura T; Odoh K; Kino Y
Microbiol Immunol; 2012 Dec; 56(12):810-6. PubMed ID: 23009167
[TBL] [Abstract][Full Text] [Related]
49. Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response.
Aljurayyan A; Puksuriwong S; Ahmed M; Sharma R; Krishnan M; Sood S; Davies K; Rajashekar D; Leong S; McNamara PS; Gordon S; Zhang Q
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563292
[TBL] [Abstract][Full Text] [Related]
50. [Local antibody immune responses in influenza patients and persons vaccinated with seasonal, pre-pandemic, and pandemic live attenuated influenza vaccines].
Donina SA; Petukhova GD; Koren'kov DA; Grigor'eva EP; Kuznetsova SA; Losev IV; Rudenko LG; Naĭkhin AN
Vopr Virusol; 2013; 58(3):37-42. PubMed ID: 24006632
[TBL] [Abstract][Full Text] [Related]
51. Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study.
Trieu MC; Jul-Larsen Å; Sævik M; Madsen A; Nøstbakken JK; Zhou F; Skrede S; Cox RJ
Clin Infect Dis; 2019 Jan; 68(3):382-392. PubMed ID: 29893797
[TBL] [Abstract][Full Text] [Related]
52. Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine.
Ohfuji S; Kobayashi M; Ide Y; Egawa Y; Saito T; Kondo K; Ito K; Kase T; Maeda A; Fukushima W; Hirota Y
Vaccine; 2017 Sep; 35(39):5303-5308. PubMed ID: 28784284
[TBL] [Abstract][Full Text] [Related]
53. Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans.
Spensieri F; Siena E; Borgogni E; Zedda L; Cantisani R; Chiappini N; Schiavetti F; Rosa D; Castellino F; Montomoli E; Bodinham CL; Lewis DJ; Medini D; Bertholet S; Del Giudice G
PLoS One; 2016; 11(6):e0157066. PubMed ID: 27336786
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
55. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
[TBL] [Abstract][Full Text] [Related]
56. Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015.
Ng S; Saborio S; Kuan G; Gresh L; Sanchez N; Ojeda S; Harris E; Balmaseda A; Gordon A
Vaccine; 2017 Oct; 35(45):6202-6207. PubMed ID: 28986036
[TBL] [Abstract][Full Text] [Related]
57. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
Gaglani M; Spencer S; Ball S; Song J; Naleway A; Henkle E; Bozeman S; Reynolds S; Sessions W; Hancock K; Thompson M
J Infect Dis; 2014 Jun; 209(11):1705-14. PubMed ID: 24363436
[TBL] [Abstract][Full Text] [Related]
58. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination.
Choi YS; Baek YH; Kang W; Nam SJ; Lee J; You S; Chang DY; Youn JC; Choi YK; Shin EC
Clin Vaccine Immunol; 2011 Sep; 18(9):1519-23. PubMed ID: 21813667
[TBL] [Abstract][Full Text] [Related]
59. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
de Lavallade H; Garland P; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; Szydlo R; Kanfer E; Macdonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K
Haematologica; 2011 Feb; 96(2):307-14. PubMed ID: 20971824
[TBL] [Abstract][Full Text] [Related]
60. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
